EP2041152A1 - D-glucopyranose-1-[3,5-bis(1,1-dimethylethyl)-4-hydroxybenzoat]verbindung und ihre derivate, deren herstellung und deren anwendungen - Google Patents
D-glucopyranose-1-[3,5-bis(1,1-dimethylethyl)-4-hydroxybenzoat]verbindung und ihre derivate, deren herstellung und deren anwendungenInfo
- Publication number
- EP2041152A1 EP2041152A1 EP06778681A EP06778681A EP2041152A1 EP 2041152 A1 EP2041152 A1 EP 2041152A1 EP 06778681 A EP06778681 A EP 06778681A EP 06778681 A EP06778681 A EP 06778681A EP 2041152 A1 EP2041152 A1 EP 2041152A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- virus
- hydroxybenzoate
- compound
- pharmaceutically acceptable
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Definitions
- the present invention relates to a compound D-Glucopyranose 1- [3,5-bis (1,1-dimethylethyl) -4-hydroxybenzoate] and its derivatives. It applies more particularly, but not exclusively, to the preparation and use of these compounds for the preparation of medicaments for the treatment and / or prevention of infections with enveloped viruses, and in particular, in humans, that of herpes, AIDS, influenza, hepatitis B and C, dengue fever, ebola and, in animals, Aujewsky's disease in pigs, for example.
- the action of these derivatives is peculiar. They do not intervene by blocking viral reproduction in the manner of virustatics but by dilating the viral lipid-protein membrane. They are virucides.
- the herpes and AIDS viruses like many others (hepatitis B & C, influenza, SARS, Ebola, etc.) are viruses surrounded by a lipidic envelope, unlike others - such as that of polyomyelitis is devoid - denominated for this, naked virus.
- Wrapped viruses or naked viruses are acellular organisms, totally dependent for their survival on the parasitic cell. Viruses do not have an energy generating system (ATP) or protein synthesis machinery. Although viral nucleic acids encode proteins, their synthesis occurs on the ribosomes of the host cell. Viruses are thus reduced to using the metabolic pathways of the cell and the capacities of synthesis of its chemical synthesis plants that are the ribosomes. Virutatics (triple therapy) by making impossible access to viral metabolic pathways also disturb those of the parasitized molecule that the virus borrows. It is better explained the very poor biological tolerance of these therapies that block viral replication without killing viruses. It greatly limits its effectiveness and its use.
- ATP energy generating system
- the present invention aims at preventing its entry. Two approaches are then possible: - hide the binding site of the host cell,
- virucides of di-tert-butyl structure such as BHT (butylhydroxytoluene) has been demonstrated by double-blind placebo-controlled clinical trials in humans, by the disappearance or abortion of Herpetic attacks by simple application of a topical as soon as the first symptoms appear.
- BHT butylhydroxytoluene
- BHT RNA viruses
- VHS DNA viruses
- BAMFORD will demonstrate that this alteration of the viral envelope results in the removal of a protein (P3) responsible for the adsorption of the virus on the membrane of the host cell.
- ALOIA by electron spin resonance studies on the composition of lipid envelopes, reveals the membrane fluidity of enveloped viruses and HIV in particular under the effect of heat or BHT.
- BHT decreases the membrane rigidity, disorganizing its structure. This disorganization, combined with loss of adsorption power, prevents recognition and fixation of the virus on the host cell membrane.
- ALOIA will experimentally confirm that an incubation for 30 minutes at 37 ° C. in 320 ⁇ g / ml of BHT causes a decrease in the viral infectivity of the H9 lymphocyte cultures by a logarithmic factor of 4.
- AVF1 octaoxyethylene glycol 3,5-di-tert-butyl-4-hydroxybenzoate
- the mode of activity of BHT is complex: o virucidal lysis of the lipido-protein envelope is explained by the hydrophobic properties of BHT.
- BHT lipido-protein envelope
- o fusion inhibitor by inability to locate and melt at the cell attachment site.
- the BHT is non-toxic for the body, it only targets the membrane coded by the virus and not that of the host cell.
- virus and membrane are no longer compatible.
- the virus can not open the door of entry of the host cell to go to reproduce there. He dies phagocyte.
- the invention provides the preparation of a compound D-Glucopyranose 1- [3,5-bis (1,1-dimethylethyl) -4-hydroxybenzoate] defined by the following formula:
- the process for preparing the compound D-Glucopyranose 1- [3,5-bis (1,1-dimethylethyl) -4-hydroxybenzoate] comprises the following steps:
- the compound according to the invention as well as its possible derivatives and addition salts with a pharmaceutically acceptable inorganic or organic acid may be presented in a composition comprising at least one pharmaceutically acceptable excipient.
- composition may be for example in the form of tablets, capsules, dragees, oral solutions or suspensions, emulsions, suppositories.
- compositions thus obtained may also contain preservatives.
- compositions such as 3,5-di-tert-butyl-4-hydroxybenzoic acid (BG4) or 3,5-di-tert-butyl 1-4- octaoxyethylene glycol hydroxybenzoate (AVF1) or a pharmaceutically acceptable derivative thereof.
- BG4 3,5-di-tert-butyl-4-hydroxybenzoic acid
- AVF1 3,5-di-tert-butyl 1-4- octaoxyethylene glycol hydroxybenzoate
- the amount of compound according to the invention and other possible active ingredients in such compositions may vary according to the applications, the age and the weight of the patient.
- BG4 3,5-di-t-butyl-4-hydroxybenzoic acid
- halides in particular bromide and chloride
- This acid has been proposed to prepare antiviral drugs for the treatment of diseases related to an infection of an individual with lipid-enveloped viruses and more particularly herpes viruses, or AIDS.
- the compound of the present invention has several advantages especially with respect to BHT and 3,5-di-t-butyl-4-hydroxybenzoic acid (BG4):
- the process for preparing about one kilogram of D-Glucopyranose 1- [3,5-bis (1,1-dimethylethyl) -4-hydroxybenzoate compound comprises the following steps:
- the first step comprises the synthesis of the acid chloride. 700 g of 3,5-di-tert-butyl-4-hydroxybenzoic acid in 1,400 ml of dioxane are dissolved in a flask with stirring. Then, 450 grams of thionyl chloride (3 equivalents) are introduced and the mixture is heated at 80 ° C. for 3 hours.
- TLC thin layer chromatography
- the second step includes an esterification
- Control of the progress of the reaction is carried out by thin layer chromatography (TLC) using a toluene / formic acid / acetone mixture, para-anisidine phthalate as developer, the frontal ratio or RF being 0.05.
- TLC thin layer chromatography
- the molecular compound RDW031 412.54 g. mol '1 is obtained with a purity of 98% checked by liquid chromatography (HPLC) and then characterized by proton NMR at 400 MHz in deuterated chloroform.
- the compound RDW031 of the present invention has several advantages over BHT and 3,5-di-t-butyl-4-hydroxybenzoic acid (BG4): - Better solubility in water which facilitates the development of more suitable drug preparation for a drug
- - BG 4 from 0.5% to 1%, ie from 0.04 to 0.02 Mol
- - AVF1 from 0.5% to 1%, ie from 0.0083 to 0.166 Mol (8.3 ⁇ 10 3 to
- BHT which has a very low toxicity and remains a reference molecule, only acts on enveloped viruses at concentrations of 8 to 10%. that is, at molar concentrations of 0.3 to 0.4 mol 100 times higher than that of RDW 031.
- D-glucopyranose 1- [3,5-bis (1,1-dimethylethyl) -4-hydroxybenzoate] is a new molecule combining a better solubility, a higher virucidal activity at lower doses than that of BHT and BG4.
- its hydrophilic pole causes disintegration of the viral envelope of the herpes simplex virus (HSV) and has no effect on the polio virus (naked virus).
- virucides can completely eliminate viral colonies and allow the rebirth of the white line, including CD4 lymphocytes and restore the body's immune defenses that HIV paralyzes.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/FR2006/001486 WO2008000920A1 (fr) | 2006-06-23 | 2006-06-23 | Compose d-glucopyranose 1-[3,5-bis(1 ,1-dimethylethyl)-4- hydroxybenzoate] et ses derives, leur preparation et leurs utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2041152A1 true EP2041152A1 (de) | 2009-04-01 |
Family
ID=37946716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06778681A Withdrawn EP2041152A1 (de) | 2006-06-23 | 2006-06-23 | D-glucopyranose-1-[3,5-bis(1,1-dimethylethyl)-4-hydroxybenzoat]verbindung und ihre derivate, deren herstellung und deren anwendungen |
Country Status (3)
Country | Link |
---|---|
US (1) | US20100016244A1 (de) |
EP (1) | EP2041152A1 (de) |
WO (1) | WO2008000920A1 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6195902B2 (ja) * | 2012-04-20 | 2017-09-13 | バギ リサーチ リミテッド | ウイルス感染症の予防および治療のための材料および方法 |
FR3058640B1 (fr) * | 2016-11-14 | 2020-06-19 | Robert Vachy | Composes pour leur utilisation dans le traitement de la grippe |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2659234B1 (fr) * | 1990-03-12 | 1994-07-01 | Fileco Sa | Composition therapeutique contenant un compose phenol et de la propolis utile contre les virus a capside lipidique, notamment les virus de l'herpes. |
WO1992008450A2 (fr) * | 1990-11-12 | 1992-05-29 | Fileco | UTILISATION ANTIVIRALE DE COMPOSE 2,6-DI-t-BUTYLPHENOL SUBSTITUE EN POSITION 4, NOTAMMENT VIS-A-VIS DES VIRUS DE L'HERPES ET DES PAPILLOMAVIRUS |
FR2721924B1 (fr) | 1994-06-30 | 1996-10-31 | Fileco Sa | Nouveaux composes 2,6-di-tert-butylphenols substitues en position 4, les compositions pharmaceutiques les contenant et leur procede de preparation |
-
2006
- 2006-06-23 US US12/306,330 patent/US20100016244A1/en not_active Abandoned
- 2006-06-23 EP EP06778681A patent/EP2041152A1/de not_active Withdrawn
- 2006-06-23 WO PCT/FR2006/001486 patent/WO2008000920A1/fr active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of WO2008000920A1 * |
Also Published As
Publication number | Publication date |
---|---|
US20100016244A1 (en) | 2010-01-21 |
WO2008000920A1 (fr) | 2008-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5428051A (en) | Methods of combating pneumocystis carinii pneumonia and compounds useful therefor | |
DK175632B1 (da) | Tofaseoplösningsmiddelbærersystem | |
LU85594A1 (de) | Oligodeoxynucleotide und polydeoxynucleotide,die mit einem bereich einer bei der virusvermehrung synthetisierten mrna hybridisieren und ihre anwendung als therapeutische wirkstoffe | |
US20080300253A1 (en) | Treatment of inflammatory disorders with praziquantel | |
CN116143705B (zh) | 一种药用化合物 | |
EP0308564B1 (de) | Zusammensetzung zur Hemmung oder Vernichtung mindestens eines einzelligen Lebewesens, enthaltend ein quaternäres Ammoniumfluorid, und Verfahren zur Herstellung dieses Salzes | |
US20090326037A1 (en) | Medicinal Agent For Treating Viral Infections | |
FR2887249A1 (fr) | Compose d-glucopyranose 1-[3,5-bis(1,1-dimenthylethyl)-4- hydroxybenzoate] et ses derives, leur preparation et leurs utilisations | |
WO2008000920A1 (fr) | Compose d-glucopyranose 1-[3,5-bis(1 ,1-dimethylethyl)-4- hydroxybenzoate] et ses derives, leur preparation et leurs utilisations | |
EP0524961B1 (de) | Azoische derivate, pharmazeutische und desinfektierende zusammensetzungen diese substanzen enthaltend, und deren verwendung gegen aids | |
DE69110897T2 (de) | Hemmung der viralen replikation. | |
US5854287A (en) | D-Propranolol metabolites useful for antioxidant activities | |
JP2000510114A (ja) | 抗酸化剤化合物 | |
EP4313155A1 (de) | Orale formulierung von ivermectin und verwendungen davon | |
WO2021208080A1 (zh) | 鱼针草内酯抗新型冠状病毒的用途 | |
Jumiati et al. | Drug Discovery of Griseofulvin: A Review | |
RU2337689C1 (ru) | Средство для лечения поверхностных микозов | |
CA2102518A1 (en) | Antifungal agents | |
US5955498A (en) | Agent for prophylaxis and therapy of diseases | |
Ibrahim et al. | Physicochemical properties, bioconversion and disposition of lipophilic prodrugs of 2′, 3′-dideoxycytidine | |
EP3166604B1 (de) | Mittel zur behandlung retroviraler infektionserkrankungen | |
CN102440981A (zh) | 天然白藜芦醇二聚体Pallidol类化合物在制药中的用途 | |
AU3423989A (en) | Antiviral composition containing aromatic polycyclic diones and nucleoside analogs and method for treating retrovirus infections | |
WO2024042554A1 (en) | A pharmaceutical composition for treatment of viral infections | |
Xiao et al. | Effects of benzimidazole compounds on mice infected with secondary cysts of Echinococcus granulosus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20090123 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
17Q | First examination report despatched |
Effective date: 20101012 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20110805 |